Redeye leaves a research update following Klaria Pharma’s Q4 2023 report published earlier today. With multiple potential inflection points in store for the year, Klaria Pharma’s main hurdle remains its financing. While the company managed to secure its immediate funding concerns through a non-dilutive loan agreement, we still anticipate a rights issue during 2024 to extend its financial runway.

https://www.redeye.se/research/988007/klaria-pharma-q4-eyes-on-the-prize?utm_source=finwire&utm_medium=RSS

Redeye